{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:25:04Z","timestamp":1791872704583,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To investigate relationships between treatment week, relative to Ytrrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y) glass microsphere calibration (i.e., specific activity and particle density), and outcomes for hepatocellular carcinoma (HCC) or colorectal cancer liver metastasis (mCRC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Multinational, multicenter study TARGET (retrospective;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009209 HCC patients) was combined with EPOCH (phase III trial;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009428 mCRC patients). Efficacy included overall response rate (ORR), overall survival (OS), progression-free survival (PFS), hepatic PFS, and tumour marker response rates. Safety included clinical and laboratory toxicity. Retrospective multicompartment dosimetry, tumour and normal tissue absorbed dose were available for TARGET; single compartment dosimetry was available for EPOCH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No efficacy relationship was found relative to treatment week for TARGET or EPOCH. mRECIST ORR in TARGET for weeks 1 and 2 were 74\/125 (59.2%) and 55\/84 (65.5%), and by RECIST 1.1 in EPOCH were 54\/142 (38.0%) and 15\/43 (34.9%), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Median OS for TARGET weeks 1 and 2 were 21.4 and 20.3\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07), and in EPOCH were 14.9 and 16.4\u00a0months, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.37). No difference in the TARGET primary endpoint of hyperbilirubinemia was noted for weeks 1 and 2, odds ratio 0.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.59. TARGET\u2009\u2265\u2009grade 3 device-related adverse events (AEs) for weeks 1 (16.8%) and 2 (26.2%) were not significantly different (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11). EPOCH rates of\u2009\u2265\u2009grade 3 asthenia for weeks 1 (9.2%) and 2 (23.3%) were statistically different (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No efficacy treatment benefit for week 2 versus week 1 was observed in TARGET or EPOCH, but week 2 treatment trended towards a higher rate and severity of specific AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07334-8","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:32:00Z","timestamp":1747863120000},"page":"4834-4846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC"],"prefix":"10.1007","volume":"52","author":[{"given":"Marnix G. E. H.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk D.","family":"Fowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeen","family":"Mahvash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth A.","family":"Padia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"7334_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-019-04588-x","volume":"47","author":"AS Pasciak","year":"2020","unstructured":"Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47:816\u201327. https:\/\/doi.org\/10.1007\/s00259-019-04588-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR2","unstructured":"Technical Report 97124387. https:\/\/www.bostonscientific.com\/en-US\/medical-specialties\/interventional-radiology\/interventional-oncology\/therasphere\/dosage-and-administration.html: Boston Scientific; 2024."},{"key":"7334_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13550-022-00911-0","volume":"12","author":"P d'Abadie","year":"2022","unstructured":"d\u2019Abadie P, Walrand S, Hesse M, Borbath I, Lhommel R, Jamar F. TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity. EJNMMI Res. 2022;12:40. https:\/\/doi.org\/10.1186\/s13550-022-00911-0.","journal-title":"EJNMMI Res"},{"key":"7334_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/MNM.0000000000001395","volume":"42","author":"P d'Abadie","year":"2021","unstructured":"d\u2019Abadie P, Walrand S, Hesse M, Annet L, Borbath I, Van den Eynde M, et al. Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. Nucl Med Commun. 2021;42:747\u201354. https:\/\/doi.org\/10.1097\/MNM.0000000000001395.","journal-title":"Nucl Med Commun"},{"key":"7334_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/cancers15030645","volume":"15","author":"CS Taswell","year":"2023","unstructured":"Taswell CS, Studenski M, Pennix T, Stover B, Georgiou M, Venkat S, et al. For hepatocellular carcinoma treated with yttrium-90 microspheres, dose volumetrics on post-treatment bremsstrahlung SPECT\/CT predict clinical outcomes. Cancers (Basel). 2023;15:645. https:\/\/doi.org\/10.3390\/cancers15030645.","journal-title":"Cancers (Basel)"},{"key":"7334_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2967\/jnumed.115.163444","volume":"57","author":"AS Pasciak","year":"2016","unstructured":"Pasciak AS, Bourgeois AC, Bradley YC. A microdosimetric analysis of absorbed dose to tumor as a function of number of microspheres per unit volume in 90Y radioembolization. J Nucl Med. 2016;57:1020\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.163444.","journal-title":"J Nucl Med"},{"key":"7334_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jvir.2023.10.011","volume":"35","author":"JW Choi","year":"2024","unstructured":"Choi JW, Suh M, Paeng JC, Kim JH, Kim HC. Radiation major hepatectomy using ablative dose yttrium-90 radioembolization in patients with hepatocellular carcinoma 5 cm or larger. J Vasc Interv Radiol. 2024;35:203\u201312. https:\/\/doi.org\/10.1016\/j.jvir.2023.10.011.","journal-title":"J Vasc Interv Radiol"},{"key":"7334_CR8","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1007\/s00259-022-05902-w","volume":"49","author":"J Roosen","year":"2022","unstructured":"Roosen J, Westlund Gotby LEL, Arntz MJ, F\u00fctterer JJ, Janssen MJR, Konijnenberg MW, et al. Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. Eur J Nucl Med Mol Imaging. 2022;49:4705\u201315. https:\/\/doi.org\/10.1007\/s00259-022-05902-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR9","doi-asserted-by":"publisher","first-page":"245010","DOI":"10.1088\/1361-6560\/aaf205","volume":"63","author":"P d'Abadie","year":"2018","unstructured":"d\u2019Abadie P, Hesse M, Jamar F, Lhommel R, Walrand S. (90)Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol. 2018;63:245010. https:\/\/doi.org\/10.1088\/1361-6560\/aaf205.","journal-title":"Phys Med Biol"},{"key":"7334_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2967\/jnumed.113.135301","volume":"55","author":"S Walrand","year":"2014","unstructured":"Walrand S, Hesse M, Jamar F, Lhommel R. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med. 2014;55:1317\u201322. https:\/\/doi.org\/10.2967\/jnumed.113.135301.","journal-title":"J Nucl Med"},{"key":"7334_CR11","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/molecules26133966","volume":"26","author":"P d'Abadie","year":"2021","unstructured":"d\u2019Abadie P, Hesse M, Louppe A, Lhommel R, Walrand S, Jamar F. Microspheres used in liver radioembolization: from conception to clinical effects. Molecules. 2021;26:3966. https:\/\/doi.org\/10.3390\/molecules26133966.","journal-title":"Molecules"},{"key":"7334_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328\u201343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nucmedbio.2018.01.001","volume":"59","author":"N Nezami","year":"2018","unstructured":"Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. (90)Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. Nucl Med Biol. 2018;59:22\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.01.001.","journal-title":"Nucl Med Biol"},{"key":"7334_CR14","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"39","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;39:3897\u2013907. https:\/\/doi.org\/10.1200\/JCO.21.01839.","journal-title":"J Clin Oncol"},{"key":"7334_CR15","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49:3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7334_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","volume":"62","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass (90)Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62:1616\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.255745.","journal-title":"J Nucl Med"},{"key":"7334_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07179-1","author":"SA Montazeri","year":"2025","unstructured":"Montazeri SA, De la Garza-Ramos C, Silver C, Paz-Fumagalli R, Lewis AR, Frey GT, et al. Achieving complete pathologic necrosis in hepatocellular carcinoma treated with radiation segmentectomy before liver transplantation: a comprehensive glass microsphere analysis. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07179-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR19","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49:3892\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05776-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR20","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1007\/s00330-021-08501-9","volume":"32","author":"S Young","year":"2022","unstructured":"Young S, Chen T, Flanagan S, Golzarian J, Sanghvi T. Realized tumor to normal ratios in hepatocellular carcinoma patients undergoing transarterial radioembolization: a retrospective evaluation. Eur Radiol. 2022;32:4160\u20137. https:\/\/doi.org\/10.1007\/s00330-021-08501-9.","journal-title":"Eur Radiol"},{"key":"7334_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/cancers14040959","volume":"14","author":"C Romano","year":"2022","unstructured":"Romano C, Mazzaglia S, Maccauro M, Spreafico C, Gabutti A, Maffi G, et al. Radioembolization of hepatocellular carcinoma with (90)Y glass microspheres: no advantage of voxel dosimetry with respect to mean dose in dose-response analysis with two radiological methods. Cancers (Basel). 2022;14:959. https:\/\/doi.org\/10.3390\/cancers14040959.","journal-title":"Cancers (Basel)"},{"key":"7334_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07229-8","author":"M Lam","year":"2025","unstructured":"Lam M, Salem R, Toskich B, Kappadath SC, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07229-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843\u201350. https:\/\/doi.org\/10.1016\/S2468-1253(22)00091-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7334_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"7334_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40658-020-00302-1","volume":"7","author":"N Meyers","year":"2020","unstructured":"Meyers N, Jadoul A, Bernard C, Delwaide J, Lamproye A, Detry O, et al. Inter-observer variability of (90)Y PET\/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization. EJNMMI Phys. 2020;7:29. https:\/\/doi.org\/10.1186\/s40658-020-00302-1.","journal-title":"EJNMMI Phys"},{"key":"7334_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.semnuclmed.2019.01.006","volume":"49","author":"E Garin","year":"2019","unstructured":"Garin E, Rolland Y, Edeline J. (90)Y-loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of 99mTc-MAA SPECT\/CT-based dosimetry. Semin Nucl Med. 2019;49:218\u201326. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.01.006.","journal-title":"Semin Nucl Med"},{"key":"7334_CR27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","volume":"50","author":"N Kokabi","year":"2023","unstructured":"Kokabi N, Arndt-Webster L, Chen B, Brandon D, Sethi I, Davarpanahfakhr A, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50:1743\u201352. https:\/\/doi.org\/10.1007\/s00259-023-06111-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR29","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jvir.2023.05.022","volume":"34","author":"N Naydenov","year":"2023","unstructured":"Naydenov N, Teplov A, Zirakchian MZ, Ruan S, Chu BP, Serencsits B, et al. Yttrium-90 activity quantification in PET\/CT-guided biopsy specimens from colorectal hepatic metastases immediately after transarterial radioembolization using micro-CT and autoradiography. J Vasc Interv Radiol. 2023;34:1556-64.e4. https:\/\/doi.org\/10.1016\/j.jvir.2023.05.022.","journal-title":"J Vasc Interv Radiol"},{"key":"7334_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/liv.13220","volume":"37","author":"E Garin","year":"2017","unstructured":"Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int. 2017;37:101\u201310. https:\/\/doi.org\/10.1111\/liv.13220.","journal-title":"Liver Int"},{"key":"7334_CR31","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-018-4064-6","volume":"45","author":"CL Ho","year":"2018","unstructured":"Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET\/CT and posttreatment (90)Y PET\/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45:2110\u201321. https:\/\/doi.org\/10.1007\/s00259-018-4064-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"AL Hermann","year":"2020","unstructured":"Hermann AL, Dieudonne A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296:673\u201384. https:\/\/doi.org\/10.1148\/radiol.2020191606.","journal-title":"Radiology"},{"key":"7334_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijrobp.2018.05.062","volume":"102","author":"SC Kappadath","year":"2018","unstructured":"Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT\/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102:451\u201361. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7334_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2967\/jnumed.119.226472","volume":"61","author":"YK Dewaraja","year":"2020","unstructured":"Dewaraja YK, Devasia T, Kaza RK, Mikell JK, Owen D, Roberson PL, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET\/CT-based dose metrics. J Nucl Med. 2020;61:104\u201311. https:\/\/doi.org\/10.2967\/jnumed.119.226472.","journal-title":"J Nucl Med"},{"key":"7334_CR35","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00259-024-06813-8","volume":"51","author":"KT Pianka","year":"2024","unstructured":"Pianka KT, Barahman M, Minocha J, Redmond JW, Schnickel GT, Rose SC, et al. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2024;51:3744\u201352. https:\/\/doi.org\/10.1007\/s00259-024-06813-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7334_CR36","doi-asserted-by":"publisher","first-page":"e231386","DOI":"10.1148\/radiol.231386","volume":"311","author":"A Sarwar","year":"2024","unstructured":"Sarwar A, Malik MS, Vo NH, Tsai LL, Tahir MM, Curry MP, et al. Efficacy and safety of radiation segmentectomy with (90)Y resin microspheres for hepatocellular carcinoma. Radiology. 2024;311:e231386. https:\/\/doi.org\/10.1148\/radiol.231386.","journal-title":"Radiology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07334-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:31:33Z","timestamp":1762327893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7334"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07334-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Marnix Lam is a consultant to Boston Scientific, Novartis, Oncosil, BD, Terumo, and Quirem, and receives research support from Boston Scientific, Novartis, Terumo, and Quirem. Etienne Garin is a consultant for Boston Scientific. Kirk Fowers is a non-commercial employee of Boston Scientific Corporation. Armeen Mahvash is a consultant for Boston Scientific, Sirtex Medical, and ABK Biomedical. He received research support from Boston Scientific, Sirtex Medical, ABK Biomedical, and Siemens Healthineers. Siddharth Padia is a consultant for Boston Scientific, Guerbet, Johnson and Johnson, Teleflex Medical, and Varian Medical Systems. Riad Salem is a consultant for AstraZeneca, Bard, Boston Scientific, Cook, Eisai, Genentech, Sirtex, and QED Therapeutics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}